摘要
新型抗TNF-α制剂赛妥珠单抗(Certolizumab pegol,CZP)为一种聚乙二醇人源化Fab'片段的抗TNF-α单克隆抗体,其对中重度克罗恩病(Crohn's disease,CD)患者可以诱导并维持缓解,促进黏膜愈合,从而提高患者生活质量。赛妥珠单抗对英夫利昔单抗治疗失去应答或者不耐受的患者仍有较好的疗效,并能促进瘘管型CD患者瘘管的闭合。与其他生物制剂相比,赛妥珠单抗可皮下注射,给药方便、不良反应少,已成为一种用于治疗CD的新型生物治疗方式。本文就赛妥珠单抗治疗CD的研究进展作一综述。
Certolizumab pegol （CDP870） is a polyethylene glycolated Fab＇ fi＇agment of a humanized anti-TNF-α monoclonal antibody. Certolizumab pegol is effective in inducing and maintaining clinical response and remission in patients with moderate to severe Crohn＇s disease, which permits to achieve mucosal healing and improve the quality of life in these patients. Certolizumab pcgol has also been shown to be beneficial to patients who lose response or are intolerant to infliximab and to promote the closure of the fistula orifice. Certolizumab pegol represents an important new therapeutic option for the treatment of Crohn＇s disease for its convenient mode of administration and less adverse events. This article reviews the recent advances in the treatment of Crohn＇s
出处
《中华临床医师杂志（电子版）》
CAS
2013年第24期360-363,共4页
Chinese Journal of Clinicians(Electronic Edition)
